Pizotifen
SIGMA/B9688 - ≥98% (HPLC)
Synonym: Pizotifen; Pizotyline; 4-
CAS Number: 15574-96-6
Empirical Formula (Hill Notation): C19H21NS
Molecular Weight: 295.44
EC Number: 239-632-9
MDL Number: MFCD00864192
Linear Formula: C19H21NS
Product Type: Chemical
| assay | ≥98% (HPLC) |
| form | powder |
| InChI | 1S/C19H21NS/c1-20-11-8-15 |
| InChI key | FIADGNVRKBPQEU-UHFFFAOYSA |
| originator | Novartis |
| Quality Level | 100 ![]() |
| SMILES string | CN1CCC(CC1)=C2c3ccccc3C |
| solubility | DMSO: ≥8 mg/mL |
| storage temp. | room temp |
| Biochem/physiol Actions: | Pizotifen is a serotonin antagonist acting mainly at the 5-HT1, 5-HT2A and 5HT2C receptors with some antihistamine activity. It is used for the prevention of vascular headache including migraine and cluster headache. |
| Biochem/physiol Actions: | Pizotifen is a Serotonin antagonist used for prophylaxis of migraine |
| Features and Benefits: | This compound was developed by Novartis . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 10, 50 mg in glass bottle |
| Symbol | ![]() GHS07,GHS08 |
| Signal word | Warning |
| Hazard statements | H302 - H361 |
| Precautionary statements | P201 - P301 + P312 + P330 - P308 + P313 |
| Hazard Codes | Xn |
| Risk Statements | 63-22 |
| Safety Statements | 36/37 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | room temp |
| UNSPSC | 12352200 |



